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Background: Patients with diabetes mellitus (DM) undergoing stent implantation have increased on-treatment platelet reactivity (HPR), which may 
contribute to a greater risk of post-procedural thrombotic events.
Objectives and Methods: ADAPT-DES was an 8,575 patient prospective, multicenter observational study of unselected patients undergoing 
drug-eluting stent implantation; routine platelet function testing was performed with the VerifyNow P2Y12 point-of-care assay following clopidogrel 
loading. We sought to examine the association between HPR and stent thrombosis (ST) according to diabetic status.
Results: A total of 2,778 enrolled patients (32.4%) had DM. Patients with DM had higher platelet reactivity units (PRU) compared to non-DM 
patients (mean PRU 219.1 vs. 175.7, p<0.0001). There was a greater proportion of patients with HPR among DM vs. no DM (for PRU>208: 56.8% 
vs. 37.2%, p<0.0001; for PRU≥230: 48.5% vs. 29.7%, p<0.0001). 30-day definite/probable ST rates were increased in DM compared to non-DM 
patients (0.72% vs. 0.33%, P=0.01). In multivariable analyses, HPR was associated with increased 30-day ST among DM patients (HR for PRU>208 = 
2.83 (95% CI 0.87-9.20), p=0.08) and in non-DM patients (HR for PRU>208 = 3.63 (95% CI 1.28-10.26), p=0.02), although the specificity was low 
in both patients with and without DM (43.3% in each group).
Conclusions: Patients with DM have more frequent HPR and higher 30-day rates of ST than patients without DM, and HPR was associated with an 
~3-fold increased hazard of 30-day ST independent of diabetic status. However, due in part to low overall event rates, the predictive capacity of HPR 
for 30-day ST is modest in both patients with and without DM.
